Transcription of CALQUENCE PRESCRIBING INFORMATION
{{id}} {{{paragraph}}}
US-33441 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the INFORMATION needed to use CALQUENCE safely and effectively. See full PRESCRIBING INFORMATION for (acalabrutinib) capsules, for oral use Initial Approval: 2017-------------------------------- RECENT MAJOR CHANGES ---------------------------------Indicat ions and Usage ( ) 11/2019 Dosage and Administration ( ) 11/2019--------------------------------- INDICATIONS AND USAGE ---------------------------------CALQUEN CE is a kinase inhibitor indicated for the treatment of adult patients with: Mantle cell lymphoma (MCL) who have received at least one prior therapy.
reactivation, fungal pneumonia, Pneumocystis jiroveci pneumonia, Epstein-Barr virus reactivation, cytomegalovirus, and progressive multifocal leukoencephalopathy (PML). Consider prophylaxis in patients who are at increased risk for opportunistic infections. Monitor patients for signs and symptoms of infection and treat promptly.
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}